http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
양덕환,정성훈,안재숙,김여경,민정준,범희승,이제중,김형준 전남대학교 의과학연구소 2015 전남의대학술지 Vol.51 No.3
The prognostic value of whole-body positron emission tomography/computed tomography(PET/CT) with 18F-fluoro-2-deoxy-D-glucose (FDG) shortly after the onset of inductionchemotherapy or mid treatment could help to predict long-term clinical outcomesin patients with Hodgkin’s or Non-Hodgkin’s lymphoma. However, FDG is nota tumor-specific substance, and it may accumulate to the point of being detected in avariety of benign conditions or at physiologic anatomical sites, which may give rise tofalse-positive interpretation. In an attempt to standardize the reporting criteria for interimPET/CT, the First International Workshop on Interim PET in Lymphoma suggestedvisual response criteria with the Deauville five-point scale, and the standardizeduptake value (SUV) has been investigated in comparison with this visual system. Aquantitative approach using the measurement of maximal SUV (SUVmax) or the reductionrate of SUVmax (ΔSUVmax) might be more appropriate in early-responsePET/CT for reducing false-positive rates or for decreasing interobserver variability ininterpretation. In this review, the predictive efficacy of PET/CT is discussed for thetreatment of aggressive lymphoma, especially in terms of an interim PET/CT-basedprognostic model.
박민호,양덕환,김미현,장재홍,장윤영,이윤경,Chun-Ji Jin,Than Nhan Nguyen Pham,Truc Anh Nguyen Thi,임미선,이현주,윤정한,이제중,홍철이 대한암학회 2011 Cancer Research and Treatment Vol.43 No.1
Purpose Various tumor antigens can be loaded onto dendritic cells (DCs) to induce a potent cytotoxic T lymphocyte (CTL) response in DC-based immunotherapy against breast cancer. However, in the clinical setting, obtaining a sufficient number of autologous tumor cells as a source of tumor antigens is a laborious process. We therefore investigated the feasibility of immunotherapy using breast-cancer-specific CTLs generated in vitro by use of alpha-type 1 polarized DCs (αDC1s) loaded with ultraviolet B-irradiated cells of the breast cancer cell line MCF-7. Materials and Methods αDC1s were induced by loading allogeneic tumor antigen generated from the MCF-7 UVBirradiated breast cancer cell line. Antigen-pulsed αDC1s were evaluated by morphological and functional assays, and the breast-cancer-specific CTL response was analyzed by cytotoxic assay. Results The αDC1s significantly increased the expression of several molecules related to DC maturation without differences according to whether the αDC1s were loaded with tumor antigens. The αDC1s showed a high production of interleukin-12 both during maturation and after subsequent stimulation with CD40L, which was not significantly affected by loading with tumor antigens. Breast-cancer-specific CTLs against autologous breast cancer cells were successfully induced by αDC1s loaded with apoptotic MCF-7 cells. Conclusion Autologous DCs loaded with an allogeneic breast cancer cell line can generate potent breast-cancer-specific CTL responses. This may be a practical method for cellular immunotherapy in patients with breast cancer.
이세련,양덕환,안재숙,김여경,이제중,최영진,신호진,정주섭,조윤영,김종광,손상균,김형준,채이수 대한의학회 2009 Journal of Korean medical science Vol.24 No.3
A refractory and resistant disease to conventional induction chemotherapy and relapsed disease are considered as the most important adverse prognostic factors for acute myeloid leukemia (AML). Sixty-one patients (median age, 33.6 yr) with relapsed or refractory AML were treated with the FLAG regimen that consisted of fludarabine (30 ㎎/㎡, days 1-5), cytarabine (2.0 g/㎡, days 1-5) and granulocyte colony-stimulating factor. Of the treated patients 29 patients (47.5%) achieved complete remission (CR). Higher CR rates were observed for patients with a first or second relapse as compared to patients with a primary refractory response or relapse after stem cell transplantation (HSCT). There was a significant difference in the response rates according to the duration of leukemia-free survival (pre-LFS) before chemotherapy (P=0.05). The recovery time of both neutrophils (≥500/μL) and platelets (≥20,000/μL) required a median of 21 and 18 days, respectively. Treatmentrelated mortality (TRM) occurred in seven patients (11.4%), of which 71.4% of TRM was caused by an invasive aspergillosis infection. After achieving CR, 18 patients underwent consolidation chemotherapy and six patients underwent allogeneic HSCT. In conclusion, FLAG chemotherapy without idarubicin is a relatively effective and well-tolerated regimen for relapsed or refractory AML and the use of FLAG chemotherapy has allowed intensive post-remission therapy including HSCT.
송가영,양덕환 대한내과학회 2023 대한내과학회지 Vol.98 No.5
Follicular lymphoma (FL) is the third most common subtype of non-Hodgkin lymphoma in Korea. Patients with FL generally present with asymptomatic lymphadenopathy, which may wax and wane for years and have indolent disease course. Most patients with FL have advanced-stage disease at diagnosis and less than 20% of patients with FL have stage I/II disease. Radiation therapy is generally accepted with the treatment of choice for limited-stage FL and results in 60-80% of 10-year overall survival rates. Patients with advanced- stage FL do not require an immediate treatment unless they have symptomatic disease, compromised end organ function, B symptoms, or cytopenia. The initial treatment of advanced-stage FL recommends rituximab-containing immunochemotherapy followed by 2 years of maintenance with rituximab, or bendamustine plus rituximab is a preferred choice because of superior progression- free survival with less toxicity than other rituximab-containing immunochemotherapy. For patients with relapsed or refractory FL, there are many options ranging from anti-CD20 monoclonal antibody alone to a combination with lenalidomide and chemotherapy or autologous stem cell transplantation. In addition, the novel approaches for relapsed or refractory FL have been applied with phosphoinositide 3-kinase inhibitor, Bruton’s tyrosine kinase inhibitor, enhancer of zeste homolog 2 inhibitor, anti-CD19 chimeric antigen receptor T-cell therapy and bispecific antibodies.